 Positive results achieved from the phase 3 MAESTRO-NAFLD-1 study using resmetirom to treat patients with NASH. Nearly half of patients in 100 mg dose arm achieved 50 reduction liver fat. Key study will be MAESTRO-NASH, which will have liver biopsy data. Results for this study expected later in 2022. 